Comparison of a Panel of Biomarkers Between Gastric Primary Cancer and the Paired Krukenberg Tumor.
To compare a panel of selected biomarkers between gastric primary cancer and the paired Krukenberg tumor, a total of 21 cases of metastatic tumors originating from stomach and the paired gastric primary cancers were collected. The expressions of a panel of selected biomarkers were tested by IHC. FISH was used to determine the status of HER2/neu in cases scored IHC 2+. The differences of the expressions of the biomarkers were evaluated between metastatic tumors and the paired gastric primary cancers. Bcl-2 was negative in all the cases. The HER2/neu expression was consistent between the gastric primary cancers and the paired metastatic tumors in 17 patients. In the other 4 cases, the HER2/neu expression was negative in gastric primary cancers but positive in the matched metastatic tumors. The concordance rate of c-MET, p53, and Ki-67 expression was 71.4%, 81.0%, and 76.2%, respectively. In conclusion, the expression of Bcl-2 is negative in all gastric primary tumors and the paired metastatic cancers. There is major concordance of the expression of HER2/neu, c-MET, p53, and Ki-67 between gastric primary cancers and the paired metastatic tumors, which suggests that the status of these biomarkers remain stable during the metastatic process.